The top after-market Nasdaq gainers Tuesday were IRobot Corporation, Enzon Pharmaceuticals Inc, Broadcom Corporation, Halozyme Therapeutics Inc, and MICROS Systems Inc. The top after-market Nasdaq losers were Vocus Inc, HomeAway Inc., Panera Bread, and Cree Inc.

Gainers

IRobot Corporation (NASDAQ:IRBT) shares climbed 16.79 percent to $28.80 in post-market trading. The company reported first quarter earnings per share of $0.29 (includes a $0.08 benefit from investment tax credits), compared with earnings per share of $0.02 in the first quarter last year. The company also increased the revenue forecast for fiscal year 2013 in the range of $485 million-$495 million from an earlier estimate $480 million-$490 million and EPS forecast for the same period from a range of $0.57-$0.72 to $0.80-$1.00.

Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) shares rose 7.05 percent to $4.10 in post-market trading after the company announced that the Board of Directors approved a $1.60 special dividend per share and intends to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to shareholders. The record date of the special dividend will be May 7, 2013, and the payment date will be June 4, 2013.

Broadcom Corporation (NASDAQ:BRCM) shares advanced 5.82 percent to $34.90 in post-market trading. The company reported a solid earnings report that beat on the top line and the bottom line. It also provided a forward guidance that was above the consensus. Revenues for the first quarter came in at $2.01 billion, $100 million above consensus estimate and earnings per share came in at $0.65 a share, beating estimate by $0.09 a share, while the company provided second quarter guidance of $2.1 billion in sales, $50 million above the current consensus.

Halozyme Therapeutics Inc. (NASDAQ:HALO) shares gained 4.59 percent to $6.84 in post-market trading. The company shares gained over 8 percent in regular trading Tuesday after it announced the initiation of a Phase 2 multi-center, randomized clinical trial evaluating PEGPH20, a proprietary, investigational drug, as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Approximately 124 patients will participate in the study and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. The primary outcome will be to measure progression-free survival between patients administered PEGPH20 to those who are not.

MICROS Systems Inc. (NASDAQ:MCRS) shares surged 3.93 percent to $45.23 in post-market trading. The company stock has a 52-week low of $39.31, a 52-week high of $58.49 and $3.45 billion in market capitalization.

Losers

Vocus Inc. (NASDAQ:VOCS) shares plunged 24.98 percent to $10.00 in post-market trading after company reported first quarter earnings per share of $0.09, $0.01 worse than the analysts' estimate of $0.10. Revenue for the quarter came in at $46.2 million versus a consensus estimate of $46.51 million.

HomeAway Inc. (NASDAQ:AWAY) shares declined 8.07 percent to $31.08 in post-market trading. The company shares dropped after the online marketplace for vacation rental homes issued disappointing revenue and earnings forecast for the second quarter.

Panera Bread Co. (NASDAQ:PNRA) shares lost 6.34 percent to $169.00 in post-market trading. The company said on Tuesday Ron Shaich will again become sole chief executive of the bakery-café chain when Bill Moreton, currently co-CEO and president, transitions to the role of executive vice chairman on Aug. 1. The company for the second quarter, forecast an earnings of $1.74 to $1.78 a share, mostly below estimates of $1.78 from analysts polled by Thomson Reuters. Same store sales at company-owned locations are expected to grow 4% to 5%. Panera also backed its full-year profit outlook.

Cree Inc. (NASDAQ:CREE) shares dropped 7.52 percent to $53.35 in post-market trading. The company expects fourth quarter 2013 EPS to be in the range of $0.34-$0.40, versus a consensus estimate of $0.37 earnings per share. Cree Inc. sees Q4 2013 revenues to be in the range of $365 million-$385 million, versus a consensus estimate of $367.58 million.

Investment